ARTICLE | Clinical News

IDEC-C2B8 chimeric antibody targeted to the CD20 receptor on B cells data

December 13, 1993 8:00 AM UTC

In a Phase I trial in 15 patients, six of nine patients receiving the three highest of five doses tested had reductions in tumor size. Two of the patients' tumors shrank by half or more, a response that has been maintained with no further treatment for five and seven months, and four more patients showed a 25 to 50 percent decrease in tumor size, the study researchers reported. The single dose depleted only CD20-positive B cells, by 24-72 hours after injection, and kept them depleted for two to three months in most patients. Two weeks after treatment, tumor biopsies showed the human-mouse pan-B antibody bound to tumor cells. ...